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Familial Alzheimer’s disease (FAD) is characterized by autosomal dominant heritability and early disease 
onset. Mutations in the gene encoding presenilin-1 (PS1) are found in approximately 80% of cases of FAD, 
with some of these patients presenting cerebellar damage with amyloid plaques and ataxia with unclear 
pathophysiology. A Colombian kindred carrying the PS1-E280A mutation is the largest known cohort of PS1-
FAD patients. Here, we investigated PS1-E280A–associated cerebellar dysfunction and found that it occurs 
early in PS1-E208A carriers, while cerebellar signs are highly prevalent in patients with dementia. Postmor-
tem analysis of cerebella of PS1-E280A carrier revealed greater Purkinje cell (PC) loss and more abnormal 
mitochondria compared with controls. In PS1-E280A tissue, ER/mitochondria tethering was impaired, Ca2+ 
channels IP3Rs and CACNA1A were downregulated, and Ca2+-dependent mitochondrial transport proteins 
MIRO1 and KIF5C were reduced. Accordingly, expression of PS1-E280A in a neuronal cell line altered ER/
mitochondria tethering and transport compared with that in cells expressing wild-type PS1. In a murine 
model of PS1-FAD, animals exhibited mild ataxia and reduced PC simple spike activity prior to cerebellar 
β-amyloid deposition. Our data suggest that impaired calcium homeostasis and mitochondrial dysfunction 
in PS1-FAD PCs reduces their activity and contributes to motor coordination deficits prior to Aβ aggrega-
tion and dementia. We propose that PS1-E280A affects both Ca2+ homeostasis and Aβ precursor processing, 
leading to FAD and neurodegeneration.
Introduction
Familial Alzheimer’s disease (FAD) is a rare variant of Alzheimer’s 
disease (AD), the most common form of dementia, which is char-
acterized by early onset (<65 years old), increased severity, and 
autosomal dominant inheritance of mutations in amyloid precur-
sor protein (APP), presenilin-1 (PS1), and PS2 (1). PS1 mutations, 
of which around 180 have been described, account for 80% of all 
FAD cases (2). There is wide clinical variability in PS1-FAD, includ-
ing epileptic seizures and cerebellar ataxia. At the neuropatholog-
ical level, brain tissue of PS1-FAD patients shows characteristic 
β-amyloid (Aβ) plaque morphology and localized damage such as 
cerebellar degeneration (3, 4). An interesting FAD mutation is PS1-
E280A (E280A-FAD), which is present in a large kindred in Colom-
bia with more than 5,000 members and around 600 affected indi-
viduals. Apart from common FAD symptoms, such as epilepsy and 
ataxia, E280A-FAD patients show typical clinical endophenotypes, 
including aphasia and variable age of onset (5). PS1 provides the 
catalytic core of the γ-secretase complex, which is involved in amy-
loidogenic processing of APP, which defines the length of the Aβ 
peptide (6, 7). PS1 mutations can increase the ratio of longer Aβ 
peptides, which are more prone to aggregation and show higher 
neurotoxicity (8). On the other hand, independent from its role in 
the γ-secretase complex, PS1 may contribute to several other func-
tions, including protein turnover (9), autophagy (10), and ER Ca2+ 
regulation (11). Up to which point these functions participate in 
the pathogenesis of FAD remains to be elucidated.
The observation that Aβ deposits occur in the cerebellum of 
PS1-E280A patients showing cerebellar dysfunction raises the 
possibility that these two phenomena are causally related. Yet, 
in the early stages, cerebellar dysfunction might in principle also 
result from molecular changes and electrophysiological distur-
bances caused by early effects of the PS1-E280A mutation before 
its impact on Aβ deposition becomes apparent (3, 12, 13). Here, we 
report in a longitudinal study that the cerebellar endophenotype 
in PS1-E280A carriers is accompanied by specific Purkinje cell (PC) 
loss and mitochondrial damage. Biochemical characterization of 
PS1 mutants suggests that Ca2+ homeostasis and mitochondrial 
transport are affected. Finally, we show that these PS1 mutations 
can cause reduced PC activity and cerebellar motor dysfunction at 
an early stage, which is compatible with a potential role of altered 
Ca2+ influx independent of Aβ deposition.
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Results
Cerebellar dysfunction in PS1-E280A carriers. We have collected ret-
rospectively clinical information from 135 E280A-FAD patients 
and 85 patients with sporadic AD (SAD) (Table 1). Cerebellar signs 
were highly prevalent in E280A-FAD patients (Figure 1A). Inten-
tion tremor and dysdiadochokinesia were the most common cer-
ebellar signs in E280A-FAD patients (Figure 1B); these symptoms 
occurred significantly more frequently in E280A-FAD patients 
than in patients with SAD (P < 0.001) (Supplemental Table 1; sup-
plemental material available online with this article; doi:10.1172/
JCI66407DS1). Thirty percent of E280A-FAD patients affected 
with cerebellar signs presented more than one sign. Furthermore, 
the presence of cerebellar signs did not correlate with age of onset 
of dementia or ApoE4 genotype status (Supplemental Figure 1A).
Given that PS1-E280A carriers show hippocampal and memory 
impairment starting in the third decade of life (5), we tested pro-
spectively cerebellar dysfunction in both cognitive symptomatic/
early stage of dementia carriers (sPS1) and asymptomatic carriers 
(aPS1); this categorization was clinically defined as reported earlier 
(ref. 14, Table 1, and Supplemental Table 2). During the 9-Hole Peg 
test, sPS1 subjects took significantly longer and made significantly 
more errors in sequence movements than both aPS1 subjects and 
normal controls (both P < 0.05) (Figure 1C and Supplemental 
Figure 1B). During the prism adaptation test (PAT), sPS1 sub-
jects also performed worse than aPS1 subjects and controls, and 
they showed visible differences in horizontal displacement during 
throwing trials (Figure 1, D and E, and Supplemental Figure 1C), 
suggesting a stepwise decrement of adaptation. Since cerebellar 
Aβ deposition occurs in the last stage of Aβ pathology (15), in this 
cohort mostly from 55 years of age onward, postdating deposition 
in other subcortical structures (16), these data indicate that the 
early motor symptoms of cerebellar dysfunction start before Aβ 
deposition becomes prominent in the cerebellum (Figure 1F).
Cerebellar damage profile in E280A-FAD. To assess cerebellar neu-
rodegeneration in E280A-FAD patients, we investigated PCs in 
the cerebellar vermes of patients with E280A-FAD, patients with 
SAD, and healthy controls morphologically (Figure 2A, Table 1, 
and Supplemental Tables 3 and 4). There were significantly 
fewer PCs in patients with AD compared with those in controls 
(P < 0.001) and fewer PCs in patients with FAD compared with 
those in patients with SAD (P < 0.05) (Figure 2B). These differ-
ences remained when groups were adjusted for age (Supplemen-
tal Figure 2A). As previously described (12), both AD groups pre-
sented cerebellar Aβ plaques, 
but with higher Aβ1–42 levels 
in the E280A-FAD group, as 
detected by ELISA (Supple-
mental Figure 2, B and D), 
and only the E280A-FAD 
group showed relevant pres-
ence of hyperphosphory-
lated Tau (pTau) pathology 
in the cerebella (Supplemen-
tal Figure 2C). Finally, we 
performed ultrastructural 
analysis of PCs in E280A-
FAD patients, patients with 
SAD, and controls. Around 
800 mitochondria were 
assessed per patient; the 
presence of abnormal mitochondria was quantified according 
to defined criteria (see Methods). PCs from E280A-FAD patients 
showed substantially more abnormally condensed mitochondria. 
There was no spatial correlation to Aβ plaques, as they could 
not be observed near (≤250 μm) PCs (Supplemental Figure 2E). 
In SAD cases and controls, mitochondria presented only post-
mortem changes (Figure 2, C and D, and Supplemental Figure 
2F). The abnormal morphology of mitochondria in PS1-E280A 
patients resembled mitophagy previously seen in the PC degener-
ation mouse (17). Thus, PS1-E280A carriers show a specific cere-
bellar endophenotype with clinical and morphological features of 
PC degeneration and mitochondrial damage, which may not be 
directly associated with Aβ plaque pathology.
Decreased ER/mitochondria tethering in PCs of PS1-E280A cerebella. 
Another noticeable feature in the ultrastructural analysis of PCs 
in PS1-E280A cerebella was that even morphologically normal 
mitochondria were rarely localized in close proximity to rough 
ER, which stands in marked contrast to their distribution in 
patients with SAD or controls (Figure 3A).When we performed 
colocalization analysis of mitochondrial marker voltage-depen-
dent anion channel (VDAC1) with ER marker PDI (Figure 3B), 
only controls and patients with SAD showed significant ER/mito-
chondria colocalization (Figure 3, B and C; P < 0.01 for controls, 
P < 0.05 for SAD). Although both presenilins are present and 
active in mitochondria-associated membranes (18), defects in ER/
mitochondria tethering were so far only linked to mutant PS2, 
but not to PS1, in cell culture (19).
Assessment of levels of proteins involved in mitochondrial function 
in the cerebella of E280A-FAD patients. Subsequently, we assessed 
mitochondrial function indirectly by measuring steady-state 
levels of mitochondrial complexes, mitochondrial phospholipid 
levels, and steady-state levels of mitochondrial proteins involved 
in fusion, fission, and transport (Figure 4A and Supplemental 
Figure 3, A–C). Assembled levels of complex IV were decreased in 
patients with AD, with E280A-FAD patients showing lower levels 
than patients with SAD and controls (P < 0.05, P < 0.001). How-
ever, only SAD cases showed significantly decreased levels of com-
plex I (P < 0.05) (Supplemental Figure 3A). These changes were 
not caused by gross alterations in phospholipid composition of 
mitochondrial membranes, as major phospholipids accumulated 
normally (Supplemental Figure 3B).
To further examine mitochondrial function, we analyzed pro-
teins involved in mitochondrial dynamics in cerebella of E280A-
Table 1
Clinical information from E280A-FAD patients and patients with SAD 
Study Group n Females (%) Age (yr) AOD (yr)
Cerebellar signs in AD E280-FAD 135 52 (38.5) 55.13 (±7.0) 49.13 (±5.2)
 SAD 85 74 (87.1) 74.84 (±9.4) 71.68 (±9.2)
Cerebellar performance in E280A carriers Controls 10 8 (80) 39.1 (±5.4) –
 aPS1 10 7 (70) 38.8 (±3.2) –
 sPS1 9 6 (66.7) 49.22 (±5.2) 47.8 (±1.5)A
Neuropathological and biochemical profile E280-FAD 10 8 (80) 56.9 (±6.7)B 45 (±4.3)
 SAD 11 8 (72.7) 77.3 (±9.1)B 69.1 (±10.3)
 Controls 10 7 (70) 63.2 (±8.4)B –
AValid only for 4 patients. BAge at death. AOD, age of onset of dementia. aPS1, asymptomatic PS1-E280A carriers; 
sPS1, symptomatic PS1-E280A carriers.
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FAD patients, patients with SAD, and controls. Mitochondrial 
marker VDAC1 was unchanged (Figure 4, A and B). Mitochondrial 
fusion protein optic atrophy 1 (OPA1) was significantly lower in 
patients with AD than in controls (SAD P < 0.05; E280A-FAD 
P < 0.01). Mitochondrial fission protein 1 (FIS1) and PTEN-in-
duced putative kinase 1 (PINK1) were significantly decreased in 
patients with SAD compared with E280A-FAD patients (P < 0.05). 
Adaptor protein mitochondrial Rho GTPase (MIRO1) was ele-
vated in patients with SAD compared with E280A-FAD patients 
and controls (P < 0.05), and motor protein kinesin heavy chain 
isoform 5C (KIF5C) was lower in E280A-FAD patients, with some, 
but not all, E280A-FAD patients showing a dramatic decrease of 
both proteins. Neither the phosphorylated form of fission protein 
dynamin-related protein 1 (pDRP1), nor the mitochondrial fusion 
protein mitofusin 2 (MFN2) or mitochondrial anchor protein syn-
taphilin showed significant alterations (Figure 4, A and B).
Since KIF5C and MIRO1 interact in transport regulation of 
mitochondria (20) and since both proteins were significantly 
decreased in some E280A-FAD patients, we analyzed their pres-
ence in synapses by preparing synaptosomal fractions and frac-
tions of mitochondria not attached to organelles (free mitochon-
dria) from cerebella of E280A-FAD patients, patients with SAD, 
Figure 1
Cerebellar ataxic phenotype in E280A-FAD patients. (A) Prevalence of cerebellar signs in E280A-FAD patients (FAD, n = 135) against their 
prevalence in patients with SAD (n = 85). (B) Distribution of cerebellar signs among affected PS1-E280A patients (n = 64). (C) Cerebellar test 
performance in asymptomatic (aPS1, n = 10) and symptomatic (sPS1, n = 9) PS1-E280A carriers as well as age-matched healthy controls (Ctrl, 
n = 10). Bar graphs represent measurement of time to completion of 9-Hole Peg test with right hands and left hands (RH and LH). (D) PAT perfor-
mances. Bar graphs for PAT shows sPS1 subjects with significantly more baseline errors. (E) sPS1 subjects showed less adaptation in PAT test 
than controls. Both groups of PS1-E280A carriers performed equally in the after-effect. *P < 0.05, data are mean ± SEM, 2-tailed t test. (F) Clinical 
progression of cerebellar dysfunction in PS1-E280A carriers. Predementia is portrayed in gray and dementia is portrayed in black alongside the 
timescale. Onset and duration of Aβ deposits in the cerebellum and seizures are depicted with a black arrow.
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and controls (Supplemental Figure 4A). In synaptosomal-enriched 
fractions, we found higher contents of VDAC1 in controls com-
pared with patients with AD (P < 0.05), with comparable contents 
of MIRO1 and elevated KIF5C in E280A-FAD patients compared 
with patients with SAD and controls (P < 0.05). Free mitochondria 
fractions showed higher contents of VDAC in patients with AD 
compared with controls (all P < 0.05), higher contents of MIRO1 
in patients with SAD when compared with controls and E280A-
FAD patients (all P < 0.05), and negligible contents of KIF5C in 
all groups (Figure 4, C and D). Decreased presence of mitochon-
dria in synaptosomes of both AD groups and increased levels of 
MIRO1 in the free mitochondria fraction only in the SAD group 
suggest that MIRO1-mediated compensatory transport is only 
taking place in the SAD group. On the other hand, the increased 
presence of KIF5C in synaptosomes, together with low levels of 
MIRO1 in the free mitochondria fraction in E280A-FAD patients, 
may indicate a lack of mitochondrial trafficking. The presence of 
abnormal mitochondria, decreased ER/mitochondria tethering, 
and downregulation and redistribution of mitochondrial trans-
port proteins in E280A-FAD patients raises the possibility that 
their Ca2+ homeostasis is affected
Decreased levels of Ca2+ channels in PS1-E280A carriers. Regulation 
of mitochondrial transport in neurons is related with synaptic 
activity and depends mainly on 2 intracellular signals, ATP/ADP 
levels and intracellular Ca2+ concentration (21). Since MIRO1-KIF–
dependent mitochondrial transport to the synapse is a Ca2+-mod-
ulated process (20) and presenilins have been shown to affect Ca2+ 
homeostasis in animal models (22), we measured steady-state levels 
of PS1 and proteins involved in Ca2+ homeostasis in the cerebella 
of our patients (Figure 5A). Levels of the C-terminal fragment of 
PS1 (PS1-CTF) were decreased and levels of Ca2+ channels, such as 
voltage-gated P/Q-type calcium channels (encoded by CACNA1A) 
and inositol 1,4,5-trisphosphate receptor type 1 and 3 (IP3R1 and 
IP3R3), were severely decreased in E280A-FAD patients (P < 0.05), 
while calbindin, a Ca2+-buffering protein, was increased (P < 0.05). 
Other Ca2+-related proteins, such as sarco/endoplasmic reticulum 
Ca2+-ATPase type 2 (SERCA2) and calretinin, were unaffected (Fig-
ure 5, A and B). Interestingly, PS1-CTF and IP3R3 levels correlated 
with mitochondrial transport proteins and Ca2+ channels only in 
E280A-FAD patients. Neither Aβ nor pTau-p181 levels correlated 
with decreased proteins in E280A-FAD patients (Table 2).
Altered mitochondrial distribution and ER tethering in a neural cell 
culture model of PS1-E280A. PS1 affects modulation of Ca2+ stores 
(11), influencing activation of mitochondrial Ca2+ uptake and 
ER/mitochondria tethering (23). In addition, ER/mitochondria 
tethering is influenced by Ca2+ stress (24). To clarify the role of 
PS1 in mitochondrial distribution and transport, we expressed 
human wild-type PS1 (PS1WT), PS1E280A, and PS1 deletion 
Δ9 (PS1Δ9) in neural SH-SY5Y cells. ER/mitochondria tethering 
was evaluated under both basal conditions and Ca2+ overload 
induced by calcimycin. PS1WT cells showed ER/mitochondria 
colocalization under basal conditions (P < 0.05) and no colocal-
Figure 2
Increased PC loss and abnormal mitochondria structure in PS1-E280A. (A) Immunohistochemical analysis and quantification of PCs in cerebellar 
vermes of age-matched controls and patients with SAD and FAD (Ctrl and FAD, n = 10; SAD, n = 11) using calbindin antibody as a marker for 
PCs. Insets in microphotographs show high-magnification views of boxed areas. Scale bar: 100 μm. (B) There are fewer PCs in patients with 
AD compared with controls (P < 0.001) and fewer PCs in patients with FAD compared with patients with SAD (P < 0.05). *P < 0.05, **P < 0.01, 
data are mean ± SEM, Mann-Whitney U test. (C) Ultrastructural analysis of PCs of age-matched controls and patients with SAD and FAD (all 
groups n = 3, representative pictures) showing nuclei (outlined in light red) and surrounding mitochondria. Mitochondria of all groups show typical 
postmortem changes (swollen mitochondria, blurry cristae). Only E280A-FAD show pathological mitochondria filled with electron dense material 
resembling mitochondria undergoing mitophagy. Insets show mitochondria (arrows). Scale bar: 1 μm. (D) Percentage of abnormal mitochondria 
in analyzed groups. *P < 0.05, data are mean ± SEM, Mann-Whitney U test. 
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ization after acute Ca2+ overload. Both PS1 mutations showed the 
opposite response, with no colocalization under basal conditions 
and increased colocalization after treatment (Figure 6, A and B; 
P < 0.05 for PS1-E280A). In addition, we evaluated mitochondrial 
transport under basal conditions in transfected cells. PS1-E280A 
showed significantly elevated mitochondrial mobility when com-
pared with PS1WT (Figure 6, C and D; P < 0.05). This might be 
favored by decreased cytosolic Ca2+ levels (25) as a result of PS1-
E280A–induced Ca2+ retention in Ca2+ stores. Since the disturbed 
Ca2+-related proteins in the PS1-E280A patients were observed 
at the end point of their chronic disease, these changes probably 
result from a long-term process. In order to assess the impact of 
chronic Ca2+ overload on the key proteins IP3R1 and MIRO1, we 
treated transfected SH-SY5Y cells with calcimycin for 16 hours. 
Figure 3
Decreased ER/mitochondria 
interaction in PS1-E280A 
PCs. (A) Ultrastructural anal-
ysis of PCs of age-matched 
controls and patients with 
SAD and FAD (all groups 
n = 3, representative pic-
tures) showing nuclei (out-
lined in light red), mitochon-
dria (light blue), and rough 
ER (light green). Boxes depict 
ER/mitochondria interfaces; 
higher magnification images 
of boxed areas are shown 
on the bottom row. E280A-
FAD mitochondria show no 
evident direct interaction with 
rough ER. Scale bar: 100 nm. 
(B) Representative confocal 
fluorescent micrographs and 
corresponding scatter plots 
of PCs from controls (n = 3) 
and patients with SAD (n = 3) 
and FAD (n = 3) using mito-
chondrial marker VDAC1 
(red) and ER marker PDI 
(green). Area within white 
boxes is shown at higher 
magnification for evaluated 
regions of interest, showing 
fewer labeled mitochondria 
and less ER colocalization 
in E280A-FAD. Scale bar: 20 
μm. (C) Pearson’s r analysis 
of at least 12 PCs in 3 cases 
for controls and patients with 
SAD and FAD. Dotted line indi-
cates Pearson’s r significance 
for colocalization for stated 
samples (n ≥ 12). *P < 0.05, 
**P < 0.01, data are mean ± 
SEM, Mann-Whitney U test.
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Figure 4
Mitochondrial dynamics and transport in cerebella of E280A-FAD patients. (A) Representative Western blots of controls (n = 5) and patients with 
SAD (n = 10) and FAD (n = 10) for mitochondrial marker protein VDAC1 and proteins involved in mitochondrial fusion (OPA1 and MFN2), fission 
(pDRP1 and FIS1), and transport (MIRO1 and mitochondrial docking protein syntaphilin); actin is used as loading control. (B) Densitometric 
quantification of proteins in A normalized to actin. (C) Subcellular fractionations on Percoll density gradient and representative Western blot 
analyses of fractions from cerebella of controls (n = 4) and patients with SAD (n = 5) and FAD (n = 5). M, membranes; M-M, membranes and 
myelin; M-S, membranes and synaptosomes; S, synaptosomes; free Mito, free mitochondria. (D) Relative percentages of VDAC1, MIRO1, and 
KIF5C in synaptosomal-enriched and mitochondrial fractions of samples in C. *P < 0.05, **P < 0.01, data are mean ± SEM, Mann-Whitney U test.
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Interestingly, PS1-E280A–transfected cells showed a significant 
decrease of IP3R1, and both PS1 mutants showed significantly 
altered levels of MIRO1 (P < 0.05) (Figure 6, E and F). Thus, the 
PS1-E280A mutation affects cellular mitochondrial distribution 
and generates a differential response to Ca2+ overload (for a sum-
mary of changes see Supplemental Table 5).
Cerebellar dysfunction and abnormal PC activity in APPsw/PS1Δ9 
mice. As cerebellar Aβ occurs in the final stages of AD (15), whereas 
E280A-FAD patients showed early motor coordination deficits, it 
is possible that abnormal cerebellar activity patterns occur before 
plaque deposition, as suggested in the time line depicted in Figure 1. 
To investigate this hypothesis, we subjected APPsw/PS1Δ9 mice 
(26) to cerebellar behavioral and in vivo electrophysiological tests 
starting at week 22, when Aβ deposits are absent, PC loss is not yet 
apparent, and there are no dystrophic mitochondria (Figure 7, A 
and B). In the ErasmusLadder task, APPsw/PS1Δ9 mice showed 
deficits in both motor performance and learning (for Methods see 
refs. 27, 28). APPsw/PS1Δ9 mice showed significantly longer step-
time values compared with controls both before (P < 0.001) and 
after (P < 0.01) a perturbation was introduced (Figure 7C). Also, 
APPsw/PS1Δ9 mice were not able to efficiently recognize and/or 
react to the provided cues meant to indicate that they should leave 
the shelter box, as the time they spent inside the box before the cue 
of departure was significantly longer than that of controls (Sup-
plemental Figure 5A) (Supplemental Figure 5A). In addition, the 
percentage of escapes (unauthorized departures) was significantly 
higher for APPsw/PS1Δ9 mice than for the control group (Sup-
plemental Figure 5B). Thus, APPsw/PS1Δ9 mice displayed a clear 
motor performance and motor learning deficit. Subsequently, we 
performed single-unit extracellular recordings of PCs in vivo in 
the cerebellar lobules (I–V) involved in locomotion. The regular-
ity (CV2 value) of simple and complex spike activities of 22-week-
old APPsw/PS1Δ9 mice was unaffected. However, they showed a 
significantly lower simple spike firing rate (P < 0.001, unpaired 
Student’s t test) (Figure 7, D and E), which has been linked to 
affected motor performance in other diseases as well (29, 30). 
Thus, a murine PS1-FAD model shows a cerebellar phenotype and 
altered PC activity from week 22 onward. Since we did not observe 
Aβ pathology until week 36, these data indicate early PCs dysfunc-
tion in PS1 mutants.
Discussion
PS1-FAD mutations show variability in age of onset and clinical/
neuropathological endophenotypes (3, 31). All pathogenic PS1-
FAD mutations are thought to affect the Aβ42/40 ratio, explaining 
the AD phenotype. Nevertheless, not all PS1 mutations modify 
APP processing in the same way (8), and even contiguous muta-
tions in PS1 sequence show different endophenotypes (3). Here, 
we describe a cerebellar endophenotype in a large cohort of PS1-
E280A carriers, characterized by abnormal mitochondria; altered 
levels of Ca2+-regulating proteins, associated with abnormal lev-
els and distribution of mitochondrial transport proteins; and 
ultimately, PC degeneration. Furthermore, we provide mecha-
nistic insights from cell culture and murine studies linking this 
Figure 5
Ca2+ deregulation leads to decreased expression of Ca2+ channels together with mitochondrial abnormal redistribution in PS1-E280A. (A) Rep-
resentative Western blots of controls (n = 5) and patients with SAD (n = 10) and FAD (n = 10) for PS1-CTF and Ca2+-related proteins in cerebella, 
such as PS1-CTF, CACNA1A, IP3R1, IP3R3, calbindin, SERCA2, and calretinin. Actin was used as loading control. (B) Dot plots for densitometric 
quantification of proteins normalized to actin. IP3R3, CACNA1A, and calbindin showed statistically significant differences between patients with 
FAD and SAD (P < 0.05). *P < 0.05, data are mean ± SEM, Mann-Whitney U test.
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endophenotype to a disturbance in Ca2+ homeosta-
sis, PC activity, and motor coordination deficits.
The endophenotype of PS1-E280A patients 
appears to be largely independent from Aβ deposi-
tions, because of four observations. First, in the ini-
tial stages of the disease, PS1-E280A carriers already 
showed deficits in cerebellar tests before Aβ deposi-
tion was likely to occur in the cerebella (15, 16). Sec-
ond, in later stages of the disease, when cerebellar 
Aβ depositions are present, abnormal condensation 
of mitochondria resembling mitophagy occurred 
at sites distant from Aβ deposits. Third, there was 
no correlation of Aβ levels with alterations in Ca2+- 
related proteins in E280A-FAD. Fourth, temporal 
and spatial segregation of symptoms in the PS1-
E280A carriers were replicated in a longitudinal 
study of APPsw/PS1Δ9 mice. Our data agree with 
the lack of a consistent correlation between cere-
bellar dysfunction and cerebellar Aβ plaque pathol-
ogy found in other PS1-FAD mutations (3); only 2 
(M139V and I143T) of 5 of the PS1-FAD mutations 
identified with cerebellar dysfunction present with 
both. Recently, a family presenting with early-onset 
dementia, cerebellar dysfunction, and cerebellar Aβ 
deposits was identified. However, aside from carry-
ing a PS1 S170F mutation, the affected patients car-
ried variant A58V of cathepsin D (32). Furthermore, 
E280A-FAD has shown previously altered Tau phos-
phorylation in the cerebellum causing pTau deposi-
tion (12). Nevertheless, we failed to see any correla-
tion between pTau levels and the observed changes in 
mitochondrial proteins or Ca2+ channels in E280A-
FAD patients, in contrast to some mechanisms pre-
viously suggested to be related to AD in general (33). 
Our results indicate that altered Ca2+ homeostasis in 
the cerebella of these patients might be yet another 
consequence, which does not necessarily depend on 
Aβ- or pTau-related processes. Finally, our data are in 
line with a study in which FAD-derived lymphoblasts 
showed altered ER Ca2+ homeostasis (34). However, 
in this lymphoblast study, PS1 E280G mutation 
showed preserved ER Ca2+ leak function. Given that 
PS1 mutations E280A and E280G have shown dif-
ferences in their clinical presentations (3) and some 
of their molecular effects (35), it is likely that their 
impact on Ca2+ homeostasis differs as well.
In principle, each of the three dysfunctions 
observed in our study (altered Ca2+ homeostasis, 
mitochondrial dysfunction, and/or PC neurodegen-
eration) may contribute to both cerebellar motor 
performance and motor learning deficits in PS1-
E280A carriers (30). In this respect, it is important 
to note that our neuropathological and biochemical 
studies in E280A-FAD patients were performed at 
the terminal stages of the neurodegenerative pro-
cess. Our patient data showed that PS1-E280A leads 
to an upregulation of calcium buffers and a down-
regulation of Ca2+ channels, which together point 
toward a compensatory mechanism to decrease high 
intracellular Ca2+ levels in PS1-E280A, as reported for 
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Figure 6
Altered ER/mitochondria tethering and transport in SH-SY5Y cells overexpressing PS1-E280A. (A) Representative confocal fluorescent micrographs 
and scatter plots of SH-SY5Y cells transiently transfected with human wild-type PS1 (PS1WT), PS1 mutation E280A (PS1-E280A), and PS1 dele-
tion Δ9 (PS1Δ9). Cells were labeled with MitoTracker Red and ER marker KDEL and evaluated under basal conditions (vehicle = DMSO) and Ca2+ 
overload (calcimycin 30 minutes). Scale bar: 10 μm. (B) Pearson’s r analysis of 30 cells in 3 independent experiments (PS1WT, PS1-E280A, and 
PS1Δ9). Dotted line indicates Pearson’s r significance for colocalization. Only PS1WT under basal conditions and PS1-E280A treated with calcimycin 
for 30 minutes showed significant colocalization. (C) Representative kymographs of SH-SY5Y cells transiently transfected with PS1WT, PS1-E280A, 
and PS1Δ9. Cells were labeled with MitoTracker Red and recorded for 4 minutes. (D) Mitochondrial mobility analysis expressed as percentage of 
mobile mitochondria. At least 12 kymographs were analyzed in 3 independent experiments. PS1-E280A SH-SY5Y cells showed increased mobility 
when compared with PS1WT cells. (E) Representative Western blots of SH-SY5Y cells transiently transfected with PS1WT, PS1-E280A, and PS1Δ9 
for IP3R1 and MIRO1 proteins. Cells were treated for 16 hours with DMSO and calcimycin. (F) Densitometric quantification of IP3R1 and MIRO1 
normalized to βIII tubulin in 3 independent experiments conducted in transfected SH-SY5Y cells. For IP3R1, only PS1-E280A showed statistically 
significant reduction between basal conditions and chronic Ca2+ overload. MIRO1 levels showed statistically significant differences in both PS1 
mutants under basal and chronic Ca2+ overload conditions. *P < 0.05, data are mean ± SEM, Mann-Whitney U test.
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other PS1 mutations (36–38). IP3Rs and calbindin findings agree 
with previous in vitro data on Ca2+ homeostasis in PS1 mutants 
(39–41). In addition, the deregulation of CACNA1A in PS1-E280A 
carriers provides ample cues for cerebellar motor discoordination. 
Patients and mouse models suffering from mutations in CACNA1A 
(30, 42) and IP3R1 (43) present with ataxia. In fact, exactly like 
APPsw/PS1Δ9 mice, CACNA1A mouse mutants can present with 
reduced simple spike firing of their PCs, leading to ataxia (44).
With regard to potential mitochondrial dysfunction, our data 
provide evidence of reduced ER/mitochondria interaction (18) 
Figure 7
Cerebellar phenotype characterization in APP/PS1 mouse model. (A) Immunohistochemical analysis of cerebella from representative APPsw/
PS1Δ9 mice at 24 weeks old and 36 weeks old, using 6E10 antibody for detecting Aβ plaques and calbindin antibody as a PC marker. 36-week-
old C57BL/6 mice were used as control. Only 36-week-old APPsw/PS1Δ9 mice showed scarce Aβ pathology. Scale bar: 100 μm. (B) Ultra-
structural analysis of mitochondria (arrows) present in PCs from representative 24- and 36-week-old APPsw/PS1Δ9 mice. Dense abnormal 
mitochondria were observed in 36-week-old APPsw/PS1Δ9 mice. Scale bar: 1 μm. (C) Motor performance and cue discrimination parameters in 
APPsw/PS1Δ9 mice. The average steptimes (± SEM) were measured in 22- to 24-week-old controls (blue; n = 12) and APPsw/PS1Δ9 mice (red; 
n = 8) on the ErasmusLadder before (t5pre–t8pre) and after (t5post–t8post) perturbations were introduced during sessions 5 to 8. Both before 
and after the perturbations the steptimes were significantly longer in the mutants (**P < 0.01, ***P < 0.001, respectively; 1-way ANOVA test). 
(D and E) Extracellular PC activity in awake mice was studied in the cerebellar lobules involved in locomotion (i.e., lobules I–V). Average firing 
frequencies of both simple spikes and complex spikes measured in APPsw/PS1Δ9 mice (22 weeks of age, n = 35 cells) compared with controls 
(n = 25 cells). Frequency and regularity of simple spike firing and complex spike firing were measured in PCs. Note that the simple spike firing 
frequency was significantly lower in APPsw/PS1Δ9 mice, but regularity and complex spike firing frequency were not affected. *P < 0.001, data 
are mean ± SEM, unpaired Student’s t test.
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and disturbed Ca2+-dependent mitochondrial transport to the syn-
apse in E280A-FAD possibly executed by MIRO1/KIF5C (20). Sim-
ilar to recent findings in amyotrophic lateral sclerosis (45), mito-
chondria of PCs were abnormally condensed, resembling those 
undergoing mitophagy. PCs in the PC degeneration mouse, an 
ataxic mouse model, have shown accumulation of mitochondria 
undergoing mitophagy, similarly to findings in E280A-FAD (17). 
Decreased levels of PINK1 in cerebella of E280A-FAD patients 
provide further evidence for mitophagy (46). Interestingly, Ca2+- 
induced stress is one of the known triggers for mitophagy (47), 
and this might be independent of the controversially discussed 
role of PS1 in autophagy (10, 48). Previously, it has been suggested 
that Aβ can induce mitophagy in AD, most likely through dys-
regulation of mitochondrial dynamics (49). Yet, we did not find 
prominent changes in mitochondrial complexes, phospholipids, 
or mitochondrial fusion/fission proteins, suggesting that these 
mitochondrial processes, which in principle might be affected 
by elevated Aβ (50, 51), are relatively intact. Nevertheless, altered 
mitochondrial dynamics have been shown to contribute to cere-
bellar ataxia (52), with mitochondrial transport playing a key role 
in PC death. ER/mitochondria tethering is affected in E280A-
FAD PCs, and PS1 mutations showed specific altered Ca2+-depen-
dent mitochondrial dynamics and decreased levels of IP3R1 and 
MIRO1 in vitro, supporting a role for PS1 in ER/mitochondria 
Ca2+ homeostasis (18) and transport, without affecting phospho-
lipid synthesis, as recently suggested (53). ER/mitochondria teth-
ering has been shown to be upregulated in a mutant APP mouse 
model and was attributed to Aβ-induced stress (54). Given that in 
our experiments both PS1 mutations showed decreased ER/mito-
chondria tethering, which was only increased under Ca2+ overload, 
it is likely independent of Aβ stress. Both presenilins are known to 
affect IP3R3 gating (39), and mutant PS2 increases mitochondria 
ER interactions under basal conditions (19). In our experiments, 
mutant PS1 showed decreased ER/mitochondria tethering under 
basal conditions, hinting toward a differential role for presenilins 
in ER/mitochondria tethering. We observed differences in vitro 
between PS1-E280A and PS1Δ9 in ER/mitochondria tethering, 
transport, and IP3R1 and MIRO1 proteins levels. These differ-
ences may be attributed to loss (in some PS1 mutants) and gain 
(in PS1Δ9) of ERCa2+ leak function (11). However, it is likely that 
long-term disturbance of Ca2+homeostasis by PS1 mutations and 
PS1Δ9 results in similar cerebellar phenotypes, as observed in 
APPsw/PS1Δ9 mice.
Regarding PC neurodegeneration, cerebellar dysfunction in 
E280A-FAD patients is similar to that in patients suffering from 
PC loss due to other diseases, such as spinocerebellar ataxia type 2 
(55), which has also been related to enhanced IP3R Ca2+ signaling 
(56). In contrast, the SAD cases in our study showed less PC loss in 
absence of motor coordination deficits. However, since the motor 
deficits and abnormal simple spike activity in the APPsw/PS1Δ9 
mutants occurred before PCs started to die, it is parsimonious to 
hypothesize that PC loss does not contribute to the very initial 
stages of the cerebellar motor deficits in PS1-E280A carriers but 
worsens the symptoms later on. Patients with SAD have a lesser 
degree of PCs loss and none of the other findings at morphological 
and biochemical levels seen in PS1-E280A patients. Thus, it is pos-
sible that PC loss observed in patients with SAD is compensated 
for by functional reserve downstream in the cerebellar nuclei (30).
Taken together, we propose that PS1-E280A leads to at least two 
distinct effects. First, it induces Ca2+ deregulation, which in turn 
affects Ca2+-related proteins, and impairs mitochondrial/ER teth-
ering and transport (Figure 8), causing abnormal activity of PCs 
and concomitantly deficits in cerebellar motor coordination (30). 
Second, it leads to an increased Aβ42/40 ratio and ultimately neu-
rodegeneration (12). This is in line with other models proposing 
dual functions of PS1 mutations involving disturbed Ca2+ regu-
lation in FAD (34). Currently, several models have been proposed 
for altered Ca2+ regulation by PS1 mutants (11), with one model 
suggesting Ca2+ leakage from the ER by a channel formed by PS1 
multimers (38) and another model suggesting IP3R-altered gat-
ing as a result of its interaction with mutant PS1 (39). Our results 
are in line with both models, showing that Ca2+ dysregulation is a 
relevant event in pathophysiology of PS1-FAD patients; however, 
they do not favor one model over the other. Interestingly, altered 
Ca2+ homeostasis has also been reported for hippocampal neurons 
in PS1 mutant models (22). As E280A-FAD carriers also show epi-
leptic seizures and hippocampal sclerosis (57) associated with dys-
trophic mitochondria (58), the consequences of Ca2+ deregulation 
may not be restricted to cerebellar PCs.
Around 40% of PS1-E280A carriers with dementia suffer from 
seizures (57, 59). Importantly, in the vast majority of cases, these 
seizures start to occur after dementia onset (Supplemental Table 4 
and ref. 57). Cerebellar toxic effects for anticonvulsants have been 
described mainly for phenytoin and carbamazepine after long-term 
chronic therapy (60, 61). Only 2 of 8 E280A-FAD patients treated 
for seizures were taking one of these drugs. The 2 FAD patients 
treated with phenytoin or carbamazepine were not distinct from 
the other E280A-FAD patients with regard to protein levels of 
markers for disturbed Ca2+ regulation (Supplemental Figure 4C). 
These facts, together with the appearance of cerebellar dysfunction 
before onset of dementia and seizures, argue against the possibil-
ity that anticonvulsant therapy forms the main cause of cerebellar 
ataxia in E280A-FAD. Since the PS1-E280A family has been selected 
for a clinical trial for AD prevention with a humanized antibody 
against oligomeric forms of Aβ (62), it will be interesting to find 
out to what extent this treatment will have success in controlling 
all aspects of cerebellar and extra-cerebellar pathophysiology of 
PS1-E280A. Our data raise the possibility that non-APP processing 
functions of PS1 play an underestimated role in PS1-FAD.
Methods
A detailed description of the methods is provided in the Supplemental 
Methods.
Clinical data
Retrospective analysis of clinical records from 220 patients with AD (Table 1 
and Supplemental Table 1) was performed, including all registered med-
ical and neurological evaluations. Patients were genotyped as previously 
described (63). Cerebellar signs were identified and assigned as present 
when two or more evaluations confirmed them. Ambiguous evaluations 
indicating other motor disturbances were excluded.
Behavioral tests
Twenty-nine subjects were tested for cerebellar function and grouped as 
follows: 9 PS1-E280A carriers showing cognitive impairment were clas-
sified as symptomatic (sPS1), 10 PS1-E280A carriers without cognitive 
impairment were classified as asymptomatic (aPS1) following previously 
described parameters (14), and, finally, 10 healthy subjects belonging to 
the PS1-E280A genealogies, without carrying the PS1-E280A mutation, 
were chosen as controls.
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Motor performance was tested in 29 subjects (Supplemental Table 2), who 
threw clay balls (weight: 10 g) at a 12 cm by 12 cm cross drawn on a large 
sheet of parcel paper centered at shoulder level and placed 2 meters in front 
of them. Subjects were instructed to make each toss overhand during the 
whole experiment, to use the right hand, and to throw the balls to the loca-
tion where they saw the target. They were seated with the head restrained in 
a device in which the prism was placed, and they had an unobstructed view 
of the target during the entire session. No directions about trunk, shoulder, 
or head/neck posture were given. However, they were not allowed to look 
down at their hands as they collected the next ball from a tray located next 
to them. Subjects were asked to throw the ball at their own pace, so they 
were free to rest if they felt tired. If such an event occurred, they were asked 
to remain as still as possible with their eyes closed. The experiment had 3 
conditions. Under each condition the subjects threw 26 balls. During the 
baseline condition (PRE) subjects did not wear prisms. After finishing the 
baseline condition, subjects were tested in the PRISM condition, during 
which they wore 20-diopter optic prisms that produce a light refraction to 
the right. Once that condition was finished, subjects had the prisms removed 
and started the POS condition, during which they continued throwing balls. 
The position at which the balls made an impact on or around the target 
was marked immediately after each throw with a marker pen by an experi-
menter standing outside the visual field of the subject. The location of the 
ball impacts was plotted sequentially by trial number (abscissa) versus hor-
izontal displacement (in centimeters) from a vertical line passing through 
the target center (ordinate). Impacts to the left of the target were plotted as 
negative values and impacts to the right were plotted as positive values. The 
3 experimental conditions were carried out consecutively after the donning 
or doffing of the prisms was completed. Three additional measures were cal-
culated from the collected data of both experiments. First, a motor perfor-
mance coefficient (PQ), or called variable error (55, 64), was calculated from 
the baseline phase. To obtain the PQ, the horizontal errors (distance from 
each impact location to a vertical line passing through the target) of the PRE 
trials were measured. The PQ is the standard deviation obtained from these 
errors. Second, an adaptation magnitude was obtained by subtracting the 
horizontal distance to the target on the final throw from that on the initial 
throw while wearing the prisms (PRISM condition). Third, an after-effect 
measurement was defined as the horizontal distance of the ball’s impact to 
the target on the first throw after removing the prisms (55).
Nine-hole peg-board test
A modified version of the 9-hole peg-board test was applied (65). Using the 
Rolyan 9-Hole Peg Test Kit, 29 subjects (Supplemental Table 2) were seated 
at a table with the board, which includes a small, shallow container hold-
ing 9 pegs as well as 9 empty holes. After a start command, the patients had 
to pick up the 9 pegs, one by one, as quickly as possible and place them in 
the 9 holes, using a predetermined order. Once all pegs were placed in the 
holes, the subjects had to remove them as quickly as possible, one by one, 
following the same order used when picking them up, and place them into 
the shallow container. Both the dominant and nondominant hands were 
tested. If a patient dropped a peg off of the board or violated the order 
of placement or removal of the pegs, the examiner stopped the timer and 
counted that as a performance error. Then, the patient started the test once 
again from the beginning. Timing began when the first peg was picked up 
and ended when the last peg was placed into the shallow container, which 
was defined as the administration time.
Human subjects and samples
Demographic data of patients involved in cerebellar performance studies 
are summarized in Table 1 and demographic data of donors involved in 
postmortem studies are summarized in Supplemental Table 3. Formalin-
fixed and frozen cerebellar tissues from patients with AD and controls were 
handled as previously described (12) and used for experiments according to 
availability and sample status (Supplemental Table 3).
Histological methods
Immunohistochemistry was performed on formalin-fixed, paraffin-embed-
ded tissue, as previously described (12), of 30 human cerebellar vermis sam-
ples (Supplemental Table 3). Sections were cut (3–5 μm), deparaffinized, 
pretreated for antigen retrieval, and probed with mouse monoclonal cal-
bindin antibody and anti-Aβ antibody (see antibody data in Supplemental 
Table 5). Primary antibodies were visualized using a standard diaminoben-
zidine streptavidin-biotin horseradish peroxidase method (Sigma-Aldrich). 
PCs were quantified in 3 different optical fields of 3 consecutive slides. 
The total number of PCs was divided by total measured length of the PC 
layer. Immunohistochemistry in mice tissue followed similar protocols 
using calbindin and 6E10 primary antibodies (Supplemental Table 5). For 
double-labeling immunofluorescence, floating thick sections (100 μm) 
from formalin-fixed cerebellar vermes from 9 individuals were prepared 
(Supplemental Table 3). Sections were bleached with a UV light for 1 hour. 
Then, sections were blocked in NH4Cl for 15 minutes, followed by over-
night blocking in FBS 10% in PBST. Posteriorly, sections were incubated at 
4°C overnight with anti-VDAC1 and anti-PDI monoclonal antibodies as 
primary antibodies (Supplemental Table 6). After washing in PBS, the sec-
tions were incubated in the dark for 45 minutes at room temperature with 
the cocktail of secondary antibodies diluted in the same vehicle solution 
as the primary antibodies. Negative controls included omission of primary 
antibodies. After washing in PBS, the sections were stained with a satu-
Figure 8
Model illustrating how PS1-E280A mutation may affect 
Ca2+ homeostasis and mitochondrial transport in cere-
bellar PCs. This scheme depicts how PCs are similarly 
affected by Aβ in familial and sporadic AD. However, 
altered Ca2+ homeostasis due to PS1-E280A mutation 
promotes mitochondrial damage and impairs mitochon-
drial trafficking. Thus, in E280A-FAD, Aβ pathology, 
mitochondrial dysfunction, and abnormal levels of Ca2+- 
related proteins contribute to abnormal PC activity and 
cerebellar ataxia. Sequence of events may include altered 
Ca2+ ER modulation (no. 1), ER/mitochondria tethering 
(no. 2), mitochondrial degeneration (no. 3), and reduced 
mitochondrial transport (no. 4). mtPS1, mutant PS1.
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pieces, poured into a glass Dounce tissue grinder type B, and homogenized 
in 4 ml homogenizing buffer with 10 even strokes. The homogenate was 
centrifuged at 1,000 g for 10 minutes at 4°C. The supernatant was diluted 
with lysis buffer. Protein electrophoresis and immunoblot was performed 
as previously described (67). Briefly, once proteins were quantified, gel 
electrophoresis SDS-PAGE was carried out using a miniprotean system 
(Bio-Rad) with a molecular weight marker of standard range (Fermentas). 
Proteins (50 μg) were loaded into each well with loading buffer (0.375 M 
Tris, pH 6.8, 50% glycerol, 10% SDS, 0.5 M DTT, and 0.002% bromophenol 
blue) and heated to 95ºC for 3 minutes before loading on the gel. After 
electrophoresis, proteins were transferred to nitrocellulose membranes 
(Bio-Rad) using an electrophoretic transfer system (Mini Trans-blot Elec-
trophoretic Transfer Cell, Bio-Rad) at 350 mA for 2 hours. The membranes 
were incubated for 1 hour in 5% nonfat milk dissolved in TTBS (20 mM 
Tris, pH 7.5, 500 mM NaCl, 0.02% Tween-20). Then, the membranes were 
incubated overnight at 4°C with primary antibody (Supplemental Table 6). 
The membranes were washed with TTBS and incubated with secondary 
antibody (anti-IgG mouse or anti-rabbit IgG 1:2500, Invitrogen) coupled 
to horseradish peroxidase for 1 hour at room temperature. Immunoreac-
tive signal was developed with the ECL Western Blotting Chemilumines-
cence System (SuperSignal West Pico Chemiluminescent Substrate, Pierce) 
and detected with a ChemiDoc System (Bio-Rad). Key proteins were tested 
in temporal cortex biopsies homogenized fresh and after 12 hours in order 
to assess the stability of proteins in the range of the postmortem times for 
samples used in the study (Supplemental Figure 3C). The images were ana-
lyzed using the quantification software ImageJ (version 1.45, NIH). All pro-
teins were studied at least twice; the results of each sample were normalized 
with respect to the values of actin and compared among groups. To mini-
mize interassay variation, the samples from all experimental groups were 
processed in parallel.
Synaptosomal and mitochondrial fractioning 
The preparation of synaptosomes from human cerebellar tissue was 
done following the protocol described by Dunkley et al. (68) with some 
modifications. In brief, 1 g human cerebellum (vermis) was washed with 
ice-cold homogenizing buffer, cut in small pieces, and homogenized in 
9 ml homogenizing buffer using a tissue grinder. The homogenate was 
centrifuged at 1,000 g for 10 minutes at 4°C. The supernatant (S1) was 
collected and diluted to 5.4 ml with homogenizing buffer. The S1 fraction 
was pipetted over a Percoll gradient (F1: 5%, F2: 10%, F3: 15%, F4: 28%) and 
centrifuged at 31,000 g for 5 minutes at 4°C in a 50 Ti rotor (Beckman 
Coulter). All fractions were collected and diluted with lysis buffer (150 mM 
NaCl, 20 mM Tris, pH 7.4, 1 mM EDTA, 10% Glycerol, 1% NP40) contain-
ing phosphatase and protease inhibitors (Roche). The protein content was 
determined using the bicinchoninic acid method (BCA Protein Assay Kit, 
Pierce). Fractions F1 to F5 were identified as membranes, membranes and 
myelin, membranes and synaptosomes, synaptosomes, and mitochondria. 
Western blot was performed, loading 60 μg protein per fraction, using 
VDAC1, MIRO1, syntaphilin, and PSD95 primary antibodies. Densitomet-
ric analysis was performed on the fractions assigning a value of 100% to the 
total sum of signal from all fractions.
Plasmids and cloning
Human PS1 cDNA was purchased from GeneCopeia (GenBank: L76517.1). 
PS1 cDNA was extracted from the shuttle vector with Bsp119I and blunted 
with Klenow polymerase, and the product was digested with XhoI. The 
cDNA was subcloned into the pcDNA3.1+/Zeo vector with or without GFP 
using the XhoI and EcoRV restriction sites. After cloning, the point muta-
tion E280A was introduced by site-directed mutagenesis (QuikChange 
Lightning Site-Directed Mutagenesis Kit, Stratagene) of wild-type human 
rated solution of Sudan Black B (Armin Baack) for 30 minutes to block the 
autofluorescence of lipofuscin granules present in nerve cell bodies, rinsed 
in PBS, and washed in distilled water. Finally, sections were mounted with 
Fluoromount G (Southern Biotech), sealed, and dried overnight. Sections 
were visualized with the use of a Leica Confocal System TCS-SP2.
Ultrastructural analysis
Ultrastructural analysis was performed using glutaraldehyde-fixed cerebel-
lar tissue from 9 patients and mice as previously described (12). Cerebellar 
tissues were fixed with glutaraldehyde and chrome-osmium, dehydrated in 
ethanol, and embedded in Epon 812 (Serva Electrophoresis GmbH). After 
polymerization, 1-μm-thick sections were cut, stained with toluidine blue, 
and checked for presence of amyloid plaques. To further process them for 
electron microscopy, relevant specimens were cut into 60- to 80-nm-thick 
sections, which were contrasted with uranyl acetate and lead solution. Sec-
tions were viewed under a LEO EM 912AB electron microscope (Zeiss). 
Criteria for defining autolytic postmortem changes were as follows: (a) 
rounded and swollen mitochondria, (b) loss of matrix, (c) disrupted cristae, 
and (d) amorphous densities inside mitochondria. Criteria for defining 
abnormal mitochondria, which resembled those undergoing mitophagy, 
were as follows: (a) shrunken mitochondria, (b) electron dense amorphous 
content, and (c) compacted cristae. The PCs that were evaluated for aber-
rant mitochondria did not contain senile plaques or were present in the 
microscopy field at magnifications used.
ELISA 
Sandwich ELISA for Aβ40, Aβ42, and pTau-p181 was performed as rec-
ommended by the manufacturer (Invitrogen). Briefly, 100 mg snap-frozen 
tissue from frontal cortices and cerebella was homogenized in 800 μl of 
5 M guanidine HCl/50 mM Tris HCl for Aβ solubilization. Homogenate 
was mixed for 4 hours at room temperature, diluted in phosphate-buff-
ered saline/5% bovine serum albumin/0.03% Tween 20, and centrifuged at 
16,000 g for 20 minutes at 4°C. Supernatant was collected and probed with 
the ELISA Kit for each antigen. Samples were measured at 450 nm in a Bio-
tek μQuant spectrophotometer and expressed as ng/mg of total protein.
Analysis of mitochondrial preparation from human cerebellar tissue 
For mitochondrial isolation, cerebellar tissue from patients (Supplemental 
Table 3) was cut into small pieces and homogenized with 10 strokes at 1,000 
rpm in a motor-driven homogenizer (B. Braun, Biotech International). The 
crude homogenate was centrifuged at 1,000 g for 10 minutes, and mito-
chondria were pelleted by centrifugation of the supernatant at 8,000 g for 
10 minutes and resuspended in freezing buffer. Protein concentration was 
determined using the Bradford protein assay. For mitochondrial complex 
determination, Blue-Native PAGE analysis was applied to crude mito-
chondria (100 μg) solubilized at a concentration of 2.5 mg/ml in solvation 
buffer supplemented with detergent (0.8% DDM). Mitochondrial extracts 
were loaded onto polyacrylamide gradient gels (3%–13%), and proteins were 
transferred onto a PVDF membrane. Alternatively, thin layer chromato-
graphic analysis of mitochondrial phospholipids was performed after lipid 
extraction from crude mitochondria, and determination of the phosphate 
concentration of extracted lipids was performed as described earlier (66). 
Briefly, 15 nmol mitochondrial phospholipids were spotted on silica plates. 
The plates were developed in chloroform/methanol/25% (v/v) ammonia 
solution (50:50:3), and phospholipid spots were visualized by immersion 
in CuSO4 in 8.5% o-phosphoric acid and subsequent charring at 180°C.
Whole cerebellar tissue Western blot analysis
Proteins were isolated from human cerebella (vermes) from AD cases and 
controls (Supplemental Table 3). For this, 500 mg tissue was cut in small 
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Kymograph plug-in. Finally, the number of movable mitochondria for each 
group was calculated as a percentage of total visible mitochondria.
Mouse model experiments 
Animals. The experiments were carried out in 20- to 36-week-old female 
APPswe/PS1dE9 (APPsw/PS1Δ9) transgenic mice and B6 controls (The 
Jackson Laboratory). The generation of the APP/PS1 mouse line was 
described previously (69).
Behavioral and motor studies in APPsw/PS1Δ9 mice. APPsw/PS1Δ9 mice were 
tested with the ErasmusLadder, a fully automated test for detecting motor 
performance, associative motor learning deficits, and cognitive phenotypes 
and learning deficits in mouse models. The ErasmusLadder consists of 
a horizontal ladder in between 2 shelter boxes, which are equipped with 2 
pressurized air outlets (Pneumax, 171E2B.T.A.0009) and a bright white LED 
spotlight in the roof (both light and air are used as cues for departure). The 
air outlets are also used to control the speed of the mouse and to prevent 
unauthorized departures (escape). The ladder has 2 × 37 rungs for the left 
and right side. All rungs are equipped with pressure sensors (produced at 
Erasmus MC), which are continuously monitored and can be used to register 
and analyze the walking pattern of the mouse instantaneously. Moreover, 
based upon the prediction of the walking pattern, the rungs can be moved 
up or down by a high-speed pneumatic slide (Pneumax, 2141.52.00.36.91) 
with a maximum of 13 mm at any moment. The computer system (National 
Instruments) that runs the real-time system to record sensor data adjusts 
air pressure, predicts future touches, calculates interventions, repositions 
slides, stores data, and operates in a fixed cycle of 2 milliseconds. Details 
regarding the device and its operations have been published previously (27). 
During the first 4 days (unperturbed sessions), mice were trained with the 
even-numbered rungs on the left side and the odd-numbered rungs on the 
right side in a descended position so as to create an alternated stepping pat-
tern with 30 mm gaps. Mice were trained to walk the ladder for 72 runs per 
day. We calculated the number of missteps that were sensed by the descended 
rungs and the steptime, which is defined as the time needed to place one 
of the front paws from one rung to the other. Associative motor learning 
trials (perturbed sessions) started on day 5 using a 15-kHz tone (Voltcraft), 
which gradually increased over 20 milliseconds to 100 dB and lasted up to 
300 milliseconds, as the conditioned stimulus, whereas a rising rung, which 
ascends 12 mm, was used as the unconditioned stimulus. The interstimulus 
interval was fixed on 285 milliseconds. To keep this time period constant, we 
observed the real-time speed of the mouse and calculated which rung would 
rise. Typically, mice learn to avoid being hit by the rung by increasing walk-
ing speed; consequently, mice will decrease their steptimes over time. Besides 
motor coordination deficits, estimated in terms of motor performance and 
associative motor learning parameters, the ErasmusLadder is capable of 
detecting cognitive phenotypes. Cognition is measured, determining the 
capability of mice to recognize the cues of departure (light or air) and to 
modify their reactions to the given cues, with the purpose of reducing their 
exposure to a stressful situation (avoidance discrimination) on the ladder, 
which is created by the presence of the unconditioned and conditioned stim-
uli during the perturbed sessions.
In vivo PC electrophysiology in APPsw/PS1Δ9 mice. APPsw/PS1Δ9 mice 
(21.9 ± 0.3 weeks old) were surgically prepared for in vivo electrophysio-
logical recordings. In short, mice were anesthetized, and an immobilizing 
construct holding a small magnet (4 × 4 × 2 mm) was placed on the frontal 
and parietal bones using Optibond (Kerr) and Charisma (Heraeus Kulzer) 
(70). A craniotomy was made in the interparietal bone, and a recording 
chamber was placed around it, allowing in vivo electrophysiological record-
ings (24). After at least 24 hours of recovery, mice were head-fixed, their 
bodies were restrained in a custom-made tube, and the extracellular PC 
activity was recorded using borosilicate glass single barrel (OD 2.0 mm, ID 
PS1 cDNA using the primer 5′...CAGCTCAGGAGAGAAATGCAAC-
GCTTTTTCCAGCTCTC...3′ and its exact inverse. The PS1 variant lack-
ing amino acids 290–319 (PS1Δ9) was generated by PCR. Two fragments 
were amplified, the first flanking from 200 nt before the ORF up to the 
beginning of the exon 9 (primers F1 5′...AACAACTCCGCCCCATTGAC-
GCAAATGGGCGGTAGGCG...3′ and 5′...CTTGTGACTCCCTTTCTGT-
GCAGGAGTAAATGAGAGCTGGA...3′) and the second from the start 
of the exon 10 up to 200 nt after the end of the ORF (primers F2 5′...
TCCAGCTCTCATTTACTCCTGCACAGAAAGGGAGTCACAAG...3′ and 
5′...CAGAATAGAAATGACACCTACTCAGACAATGCGATGC...3′). The 
fragments were purified using a PCR Purification Kit (Fermentas), and 
then a new PCR was performed using the F1 forward primer and the F2 
reverse primer to homologize the halves. The product was amplified using 
the CloneJet system (Fermentas) following the recommendation of the 
manufacturer. The PS1Δ9 cDNA was subcloned into the pcDNA3.1+/Zeo 
vector using the XhoI and EcoRI restriction sites.
Ca2+ overload assays in SH-SY5Y cell culture
SH-SY5Y human neuroblastoma cells were grown in supplemented 
DMEM-F12 and were transiently transfected with pcDNA3.1+/Zeo-PS1wt, 
pcDNA3.1+/Zeo-PS1E280A, and pcDNA3.1+/Zeo-PS1Δ9 using Lipofect-
amine 2000 (Invitrogen) for 24 hours. Cultured cells were treated with 
7 nM calcimycin (Sigma-Aldrich) for 30 minutes or 16 hours. DMSO 
was used as vehicle. After treatment, cells were incubated with 250 nM 
MitoTracker Red CMXRos (Invitrogen) for 30 minutes, washed, fixed, and 
permeabilized. For chronic Ca2+ overload assay, cells were transfected for 
24 hours and then treated with calcimycin (7 nM) or DMSO for 16 hours. 
Cells were collected and incubated for 30 minutes in lysis buffer containing 
proteases and phosphatases inhibitors. Lysates were centrifuged at 18,000 g 
for 15 minutes, and supernatant was collected for experiments. Total pro-
tein concentration was evaluated with BCA assay, and samples were pre-
pared for Western blotting as described for tissue samples.
Immunofluorescence in transfected SH-SY5Y
After 30 minutes of treatment with calcimycin, SH-SY5Y cells were incu-
bated for 30 minutes with MitoTracker Red CMXRos, washed with PBS 
3 times, and subsequently fixed with cooled 95% ethanol and 5% glacial 
acetic acid for 10 minutes. Fixed cells were washed 3 times and perme-
abilized with PBS and 0.2% Triton X-100 for 10 minutes. The cells were 
washed 3 times with PBS and incubated overnight with primary antibody 
(KDEL mouse monoclonal antibody 1:100, Invitrogen) diluted in incuba-
tion buffer (PBS, 0.3% Triton X-100, 1% BSA) at 4°C in a wet chamber. 
Then, the cells were washed 3 times with PBS and incubated with Alexa 
Fluor 350 secondary antibody (1:2,500, Invitrogen) diluted in incubation 
buffer for 1 hour. After the cells were washed 4 times with PBS, they were 
mounted on slides using Fluoromount-G (Southern Biotech). Cells were 
examined under a confocal microscope (Leica TCS SP5). Confocal images 
were analyzed individually to confirm the transfection and to observe the 
mitochondrial distribution. Cells incubated only with secondary antibod-
ies were used as negative control.
Evaluation of mitochondrial transport in SH-SY5Y 
SH-SY5Y cells were plated and transfected in 3-cm glass bottom cell cul-
tures dishes and incubated for 30 minutes with MitoTracker red CMXRos. 
Cells were recorded live for 4 minutes using a spinning disc microscope 
(Perkin Elmer Ultraview Vox). Recordings were analyzed and mitochon-
drial movements were evaluated in single tracks for selected cells once suc-
cessful transfection was assessed with GFP-positive fluorescence. At least 
10 recordings obtained in 3 independent experiments were studied, and 
kymographs were prepared from each track using ImageJ software and the 
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Antioquia in Medellin (Colombia) and the Netherlands Brain Bank in 
Amsterdam (The Netherlands). Animals used for this study were main-
tained under standard animal housing conditions in a 12-hour-dark/light 
cycle with free access to food and water. Animal care was in accordance 
with ethical guidelines (European Communities Council Directive 86/609/
EEC) and approved by the local ethical committee (Erasmus).
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1.16 mm) or double barrel pipettes (Septum Theta, OD 1.5 mm, ID 1.02 
mm; both WPI) filled with 2 M NaCl for recordings, with the second barrel 
filled with 0.1% to 0.2% Alcian Blue solution. Electrodes were advanced 
into cerebellar lobules I–V by a hydraulic microdrive (Narishige). PCs were 
identified by the firing of complex spikes and were confirmed to be from a 
single unit by the presence of a pause after each complex spike (not differ-
ent in APP/SP1 mutant vs. control mice; data not shown). The minimum 
recording duration was 120 seconds, and several dye injections, followed 
by histochemical analysis, confirmed that the recordings were from lob-
ules I to V. Raw recorded signals were amplified, filtered (30 Hz to 10 kHz 
with notch filter, CyberAmp), digitized (Power 1401, CED), and stored 
for off-line analysis (sampled at 25 kHz, Spike2, CED). Analysis of in vivo 
extracellular PC recordings was performed using the Spike Train Toolbox 
(Neurasmus B.V., http://www.neurasmus.com) for Matlab (Mathworks). 
For each cell, the mean firing rate and mean and median CV2 were deter-
mined for simple and complex spikes. The CV2 value is a measurement of 
the regularity of the firing from spike to spike, calculated as the mean or 
median of 2 • | ISI(n + 1) – ISI(n) | / ISI(n + 1) + ISI(n), where ISI stands for 
the interspike interval and n stands for the ISI number.
Statistics 
Data were tabulated in Microsoft Excel data sheets and analyzed using 
SPSS 17 statistical software (SPSS Inc.) or GraphPad Prism 5 (GraphPad 
Software). Data were analyzed for determining normal distribution with 
Kolmgorov-Smirnov and Shapiro-Wilk tests. Mean comparison of para-
metric variables was performed with 2-tailed Student’s t test and 1-way 
ANOVA. Nonparametric variables were studied with the Mann-Whitney U 
and Kruskal-Wallis test. Intensity colocalization analysis was performed 
using Pearson’s coefficient, and its significance was assigned according to 
the number of samples analyzed per group. Binomial variable comparison 
was performed using χ² test. Correlation analyses for continuous variables 
were performed using Spearman’s rank coefficient. Statistical significance 
levels of all analyses were set at P < 0.05.
Study approval 
All clinical records for retrospective analyses were obtained under signed 
consent from the patients or their families for participation in the fol-
low-up of the E280A-FAD study. All living participants of the study signed 
informed consent for clinical examination, clinical data handling, and 
functional tests. Postmortem tissue was obtained after donor consent 
according to pertaining laws in Colombia, The Netherlands, and Germany 
and approved by local ethical boards, if appropriate, at the University of 
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